Teachers Retirement System of The State of Kentucky lessened its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 2.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 273,650 shares of the company's stock after selling 7,999 shares during the period. AbbVie accounts for approximately 0.5% of Teachers Retirement System of The State of Kentucky's investment portfolio, making the stock its 29th biggest position. Teachers Retirement System of The State of Kentucky's holdings in AbbVie were worth $54,040,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. Fairway Wealth LLC purchased a new position in AbbVie during the second quarter worth approximately $26,000. Ridgewood Investments LLC purchased a new position in shares of AbbVie during the 2nd quarter worth $27,000. Groupama Asset Managment grew its holdings in shares of AbbVie by 40.3% in the third quarter. Groupama Asset Managment now owns 135,749 shares of the company's stock valued at $27,000 after purchasing an additional 38,974 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in shares of AbbVie in the third quarter valued at about $28,000. Finally, Quest Partners LLC increased its position in AbbVie by 4,140.0% during the second quarter. Quest Partners LLC now owns 212 shares of the company's stock worth $36,000 after purchasing an additional 207 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts recently issued reports on ABBV shares. Guggenheim raised their price objective on AbbVie from $212.00 to $221.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Morgan Stanley reduced their price target on shares of AbbVie from $231.00 to $224.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 12th. Wells Fargo & Company upped their price objective on AbbVie to $195.00 and gave the stock a "buy" rating in a research report on Tuesday, November 19th. Barclays increased their price target on AbbVie from $200.00 to $212.00 and gave the company an "overweight" rating in a research report on Monday, October 7th. Finally, BMO Capital Markets lowered their price objective on AbbVie from $228.00 to $208.00 and set an "outperform" rating for the company in a research report on Tuesday, November 12th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and an average target price of $202.19.
Get Our Latest Analysis on ABBV
Shares of ABBV stock opened at $175.76 on Wednesday. The firm's 50-day simple moving average is $186.35 and its 200-day simple moving average is $182.67. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. AbbVie Inc. has a 1-year low of $150.16 and a 1-year high of $207.32. The firm has a market cap of $310.59 billion, a P/E ratio of 61.03, a PEG ratio of 2.01 and a beta of 0.58.
AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.28 billion. During the same period in the prior year, the firm earned $2.95 EPS. The firm's quarterly revenue was up 3.8% compared to the same quarter last year. As a group, equities analysts forecast that AbbVie Inc. will post 10.95 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a $1.64 dividend. This is a positive change from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a yield of 3.73%. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie's payout ratio is currently 215.28%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.